2019
P1.04-28 COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer
Herbst R, Barlesi F, Paz-Ares L, Raben D, Aggarwal C, Bothos J, Samadani R, He P, Angra N, Martinez P. P1.04-28 COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2019, 14: s450-s451. DOI: 10.1016/j.jtho.2019.08.931.Peer-Reviewed Original ResearchStage III non-small cell lung cancerNon-small cell lung cancerCell lung cancerLung cancerNovel agentsDurvalumabCancer
2018
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). Journal For ImmunoTherapy Of Cancer 2018, 6: 75. PMID: 30012210, PMCID: PMC6048854, DOI: 10.1186/s40425-018-0382-2.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerImmune checkpoint inhibitorsCell lung cancerCheckpoint inhibitorsLung cancerDurable responsesConsensus statementStage III non-small cell lung cancerAdvanced non-small cell lung cancerCancer consensus statementSequencing of therapySecond-line settingAppropriate patient selectionOnly treatment optionAdverse event managementCancer-related mortalityImmunotherapy of cancerEvidence-based recommendationsNew treatment approachesStrength of evidenceAdvanced diseasePatient selectionTargetable mutationsTreatment optionsCancer immunotherapy
2011
Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer.
Komaki R, Blumenschein G, Wistuba I, Lee J, Allen P, Wei X, Welsh J, O'Reilly M, Herbst R, Tang X, Meyn R, Liu D, Hong W. Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer. Journal Of Clinical Oncology 2011, 29: 7020-7020. DOI: 10.1200/jco.2011.29.15_suppl.7020.Peer-Reviewed Original ResearchStage III non-small cell lung cancerNon-small cell lung cancerPhase II trialCell lung cancerII trialLung cancerChemoradiotherapyPatientsRadiotherapyErlotinibCancerTrials
2010
Chemoradiotherapy With or Without AE-941 in Stage III Non–Small Cell Lung Cancer: A Randomized Phase III Trial
Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong MT, Saxman S, Kelaghan J, Bleyer A, Fisch MJ. Chemoradiotherapy With or Without AE-941 in Stage III Non–Small Cell Lung Cancer: A Randomized Phase III Trial. Journal Of The National Cancer Institute 2010, 102: 859-865. PMID: 20505152, PMCID: PMC2902826, DOI: 10.1093/jnci/djq179.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsAntineoplastic Combined Chemotherapy ProtocolsBiological ProductsCarcinoma, Non-Small-Cell LungCartilageChemotherapy, AdjuvantDisease-Free SurvivalDouble-Blind MethodFemaleHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedMultivariate AnalysisNeoplasm StagingRadiotherapy, AdjuvantTissue ExtractsTreatment OutcomeConceptsNon-small cell lung cancerStage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerProgression-free survivalTumor response rateCell lung cancerOverall survivalAE-941Lung cancerPlacebo groupClinical trialsUnresectable stage III NSCLC patientsResponse rateStage III NSCLC patientsPhase III clinical trialsAcademic oncology centerCommon grade 3Kaplan-Meier methodPhase III trialsShark cartilage extractTarget sample sizeToxic effectsChest radiotherapyConcurrent chemotherapyEligible patients
2007
A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non- small cell lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303)
Lu C, Lee J, Komaki R, Herbst R, Evans W, Choy H, Desjardins P, Esparaz B, Truong M, Fisch M. A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non- small cell lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303). Journal Of Clinical Oncology 2007, 25: 7527-7527. DOI: 10.1200/jco.2007.25.18_suppl.7527.Peer-Reviewed Original ResearchNon-small cell lung cancerStage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerMedian survival timeConcomitant chemoradiotherapyInduction chemotherapyOverall survivalPerformance statusMedian age 63 yearsExperienced grade 3Site of enrollmentHigher adverse eventsPlacebo-controlled trialPhase III studyType of chemotherapyAge 63 yearsCell lung cancerShark cartilage extractMaintenance therapyMedian followPrimary endpointStage IIIBStudy drugAdverse eventsEligible subjects
2005
A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell Lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303): An interim report of toxicity and response
Lu C, Komaki R, Herbst R, Evans W, Lee J, Truong M, Moore C, Choy H, Bleyer A, Fisch M. A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell Lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303): An interim report of toxicity and response. Journal Of Clinical Oncology 2005, 23: 7144-7144. DOI: 10.1200/jco.2005.23.16_suppl.7144.Peer-Reviewed Original Research
2003
O-311 A phase III study of Æ-941 (Neovastat®) with induction chemotherapy (IC) and conconmitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim analysis of toxicity and response
Lu C, Komaki R, Herbst R, Evans W, Smith T, Moore C, Kolbye S, Choi N, Choy H, Bleyer A. O-311 A phase III study of Æ-941 (Neovastat®) with induction chemotherapy (IC) and conconmitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim analysis of toxicity and response. Lung Cancer 2003, 41: s90. DOI: 10.1016/s0169-5002(03)91969-6.Peer-Reviewed Original ResearchInduction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.
Wirth LJ, Lucca J, Ostler P, Fidias P, Lynch C, Jänne PA, Herbst RS, Johnson BE, Sugarbaker DJ, Mathisen DJ, Lukanich JM, Choi NC, Berman SM, Skarin AT. Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study. Clinical Cancer Research 2003, 9: 1698-704. PMID: 12738723.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage III non-small cell lung cancerCT/RTMaximum-tolerated doseCell lung cancerConcurrent radiotherapyLung cancerDose levelsConcurrent weekly carboplatinGrade 3 toxicityPathologic complete responsePhase II studyInduction docetaxelTrimodality treatmentWeekly carboplatinWeekly docetaxelII studyOverall survivalStage IIIAComplete responseSurgical patientsSubsequent radiotherapyNew regimenInduction CTGrade 3
2000
Gemcitabine (G) with concurrent chest radiation (XRT) followed by consolidation chemotherapy with gemcitabine plus cisplatin (CDDP): A phase I trial for patients with stage III non-small cell lung cancer (NSCLC)
Fossella F, Zinner R, Komaki R, Jung M, Jhingran A, Glisson B, Pisters K, Stevens C, Khuri F, Kurie J, Lee J, Herbst R, Liao Z, Hong W. Gemcitabine (G) with concurrent chest radiation (XRT) followed by consolidation chemotherapy with gemcitabine plus cisplatin (CDDP): A phase I trial for patients with stage III non-small cell lung cancer (NSCLC). Lung Cancer 2000, 29: 111-112. DOI: 10.1016/s0169-5002(00)80369-4.Peer-Reviewed Original ResearchA phase I study of carboplatin (Car) and docetaxel (Doc) followed by weekly Car/Doc with concurrent radiotherapy (CT/RT) in patients (pts) with stage III non-small cell lung cancer (NSCLC)
Skarin A, Lynch C, Lucca J, Boral A, Lynch T, Herbst R, Berman S, Choi N, Mathisen D, Sugarbaker D. A phase I study of carboplatin (Car) and docetaxel (Doc) followed by weekly Car/Doc with concurrent radiotherapy (CT/RT) in patients (pts) with stage III non-small cell lung cancer (NSCLC). Lung Cancer 2000, 29: 112. DOI: 10.1016/s0169-5002(00)80372-4.Peer-Reviewed Original ResearchNon-small cell lung cancerStage III non-small cell lung cancerCell lung cancerConcurrent radiotherapyLung cancerPhase I